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late effects secondary to ra-
diation has led to the devel-
opment of more aggressive
chemotherapy regimens
given without the routine use
of consolidative radiation
therapy. We found that posi-
tron emission tomography
ecomputed tomography im-
aging can help identify pa-
tients at high risk of
progression who should be
considered for additional
therapy beyond
chemotherapy.without RT. We also evaluated the ability of positron emission tomographyecomputed
tomography (PET-CT) to identify patients at risk of relapse.
Methods and Materials: We retrospectively identified 97 patients with diagnoses of
stage I/II PMBCL treated at our institution between 2001 and 2013. The clinical char-
acteristics, treatment outcomes, and toxicity were assessed. We analyzed whether post-
chemotherapy PET-CT could identify patients at risk for progressive disease according
to a 5 point scale (5PS) Deauville score assigned.
Results: Among 97 patients (median follow-up time, 57 months), the 5-year overall
survival rate was 99%. Of patients treated with R-CHOP, 99% received RT;
R-HCVAD, 82%; and R-EPOCH, 36%. Of 68 patients with evaluable end-of-
chemotherapy PET-CT scans, 62% had a positive scan (avidity above that of the medi-
astinal blood pool [Deauville 5PS Z 3]), but only 9 patients experienced relapse
(nZ1) or progressive disease (nZ8), all with a 5PS of 4 to 5. Of the 25 patients
who received R-EPOCH, 4 experienced progression, all with 5PS of 4 to 5; salvage
therapy (RT and autologous stem cell transplantation) was successful in all cases.
Conclusion: Combined modality immunochemotherapy and RT is well tolerated and
effective for treatment of PMBCL. A postchemotherapy 5PS of 4 to 5, rather than 3 to
5, can identify patients at high risk of progression who should be considered for therapy
beyond chemotherapy alone after R-EPOCH.  2015 The Authors. Published by Else-
vier Inc. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).IntroductionPrimary mediastinal B cell lymphoma (PMBL) is a distinct
clinicopathologic entity characterized by a large medias-
tinal mass, a locally aggressive presentation, and a predi-
lection for young women in their fourth decade (1, 2).
Originally described in the 1980s and later shown to ac-
count for roughly 2% of all non-Hodgkin lymphomas,
PMBL is thought to originate from a thymic medullary B
cell. Tumor cells express B celleassociated antigens but
share some features with nodular sclerosis Hodgkin lym-
phoma, including CD30 staining in >80% of cases and
pleomorphic tumor cells with occasional Reed-Stern-
bergelike features and a gene expression pattern that shares
about one third of genes with nodular sclerosis Hodgkin
lymphoma (3-7). Bulky disease >10 cm is not uncommon,
often with extramediastinal extension into the adjacent
chest wall, lung, and pericardium with pleural and cardiac
effusions; however, distant disease at diagnosis is uncom-
mon (8, 9). Relapses, on the other hand, tend to involve
distant extranodal sites including the liver, kidneys, adrenal
glands, gastrointestinal tract, ovaries, pancreas, and central
nervous system (10-12).
Initial therapy for patients with PMBL includes
anthracycline-based chemotherapy, the outcomes of which
have been improved by the addition of CD20-targeted
therapy (13-16). Given the aggressiveness, tumor burden,
and bulk associated with this disease, consolidative radia-
tion therapy (RT) has historically been considered a key
component of therapy. Several retrospective studies have
highlighted the role of RT in converting partial responses to
complete responses and in maintaining local control inpatients with complete responses to upfront chemotherapy
(13, 14, 17-19). Most recently, however, the role of RT has
been challenged because of the excellent outcomes reported
in a small series from the National Cancer Institute (NCI)
in which 51 patients with PMBL were treated with ritux-
imab, vincristine, and prednisone in combination with
dose-adjusted etoposide, doxorubicin, and cyclophospha-
mide (R-EPOCH) in a single-arm prospective phase II
study (20). Use of this regimen, coupled with serial imag-
ing with 18fluorodeoxyglucose (FDG) positron emission
tomography and computed tomography (PET-CT), revealed
a 5-year event-free survival rate of 93%. Three patients had
persistent or progressive disease identified by PET-CT after
R-EPOCH; 2 received salvage RT and the third underwent
excisional biopsy. The overall survival (OS) rate in this
small group was 97%; 1 patient died of treatment-related
acute myeloid leukemia.
Interest has increased in defining whether post-
immunochemotherapy PET-CT can be valuable for guiding
subsequent treatment decisions for patients with PMBL,
especially when mediastinal RT is being considered. A
5-point scale for defining PET-CT positivity has proved
robust for patients with Hodgkin lymphoma, with uptake
exceeding that of the mediastinal blood pool (MBP) sug-
gesting the possibility of residual disease (21). In the largest
prospective study of PET-CT in PMBL done to date, the
International Extranodal Lymphoma Study Group (IELSG)
obtained and centrally reviewed PET-CT scans from 115
patients after immunochemotherapy (22). In that group,
53% of patients had uptake greater than the MBP after
immunochemotherapy, but outcomes were nevertheless
excellent, with a 5-year OS rate of 92%. However, RT was
generally given universally in that study, and it is unclear
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progression-free survival (PFS), particularly in light of the
significant proportion of patients with positive scan findings
after initial immunochemotherapy. In a recent retrospective
study from the University of Bologna in which post-
immunochemotherapy PET-CT was used to assign patients
to undergo RT or observation, the disease-free survival rates
at 10 years were equivalent between groups (90.7% and
90%, PZ.85) (23), suggesting that (1) RT may have a role
as salvage therapy for persistent disease after systemic
therapy; and (2) PET-CT may have a role in identifying
patients who do not require additional treatment after in-
duction immunochemotherapy.
To address these open questions, we retrospectively
reviewed the outcomes in patients with stage I/II PMBL
diagnosed and treated at our institution between 2001 and
2013 with 1 of 3 main rituximab-containing regimens: rit-
uximab, cyclophosphamide, doxorubicin, vincristine, and
prednisone (R-CHOP); rituximab, fractionated cyclophos-
phamide, vincristine, doxorubicin, and dexamethasone
(R-HCVAD); or R-EPOCH. The two goals of this study
were (1) to evaluate the outcome in patients treated with
and without thoracic RT; and (2) to evaluate the ability of
PET-CT to identify patients at risk for local relapse.
Methods
After appropriate institutional board review approval, we
retrospectively identified patients with newly diagnosed,
Ann Arbor stage I/II PMBL that had been histologically
confirmed and treated with rituximab-based treatment at
our institution between 2001 and 2013. Patients who had
been referred for evaluation or treatment of relapsed dis-
ease after initial therapy elsewhere were excluded. Patients
who had received primary systemic therapy with appro-
priate follow-up imaging but had received RT elsewhere
were included if details of the RT (such as dose, target, and
modality) could be obtained. Patients with pleural effusion
were considered to have limited-stage disease unless
pathologic confirmation of effusion involvement was ob-
tained. Bulky disease was defined as disease that was >10
cm in axial diameter. The International Prognostic Index
was determined for all patients based on age (over or under
60 years), Eastern Cooperative Oncology Group perfor-
mance status (1 vs 2), serum lactate dehydrogenase
level (normal vs elevated), number of extranodal sites (1
vs >1), and disease stage (I/II vs III/IV).
Chemotherapy
All patients had been treated with rituximab-containing
regimens. Most patients received R-CHOP, R-HCVAD, or
R-EPOCH. The 8 patients who received a mixed regimen
were grouped according to either the regimen given for the
greatest number of cycles or, if the number of cycles was
equivalent (eg, 3þ3), the most aggressive regimen (withR-CHOP considered the least aggressive and R-EPOCH
and R-HCVAD considered equivalent).
Imaging assessment
Computed tomographic scans with contrast medium were
obtained from all patients before and after immunoche-
motherapy. Functional imaging was done 3 to 6 weeks after
completion of systemic therapy. Gallium scanning was used
for postimmunochemotherapy functional imaging before
2002, and PET or PET-CT was used afterward. In most
cases, when the postimmunochemotherapy PET-CT scan
showed evidence of uptake, additional PET-CT scans were
obtained, either after RT (when radiation was given) or
serially after immunochemotherapy for patients who did
not receive RT.
Two experts in the interpretation of PET-CT scans
(1 nuclear medicine physician and 1 radiologist) indepen-
dently reviewed the postimmunochemotherapy and post-
radiation PET-CT scans while blinded to the identities of
the patients. Response assessment was based on a 5-point
scoring system (5PS, also known as the Deauville criteria),
initially defined at a consensus conference in Deauville,
France, in 2009 and subsequently updated (24, 25). The
5PS defines FDG uptake relative to FDG in the mediastinal
and liver blood pools as follows: (1) no uptake; (2) uptake
greater than or equal to that in the mediastinum; (3) uptake
greater than that in the mediastinum but less than or equal
to that in the liver; (4) uptake moderately higher than that in
the liver; and (5) uptake markedly increased compared with
the liver; new sites of disease; or both.
According to the revised Lugano classification for
response assessment in non-Hodgkin lymphoma published
in 2014, patients with a 5PS score of 1 to 2 with or without
a residual mass are considered to have a complete response
(26). Partial response is defined as a 5PS score of 4 to 5
with a residual mass of any size. Stable disease is defined as
stable FDG avidity with a score of 4 to 5, and progressive
disease is defined as a 5PS of 4 to 5 with an increase in
intensity of uptake from baseline, with or without new avid
lesions. The response of patients with a 5PS score of 3 is
now considered ambiguous, and interpretation of this
finding is based on the timing of assessment, the treatment,
and the clinical context (26). In previous definitions of
response assessment by the International Harmonization
Project in Lymphoma, a positive scan was defined as
persistent uptake in a residual mass that was above that of
the mediastinal blood pool (ie, a 5PS of 3) (21).
Radiation therapy
The RT was administered as 3-dimensional conformal RT,
proton beam RT, or intensity modulated RT (IMRT). IMRT
was generally used after 2010 and involved a “butterfly”
technique (27). Radiation was initiated 3 to 6 weeks after
the completion of systemic therapy to an intended dose of
Table 1 Patient characteristics
Characteristic n
Age, y
Median (range) 35 (19-70)
No. 50 10 (10.3%)
Sex
Male 43 (44%)
Female 54 (56%)
B symptoms
Yes 25 (26%)
No 72 (74%)
Disease stage
I 32 (33%)
II 56 (67%)
Bulky disease
>10 cm axial diameter 50 (51%)
>7.5 cm axial diameter 73 (75%)
Mean axial diameter, cm 10.2
Extramediastinal contiguous disease
Yes 12 (12.4%)
No
IPI
0 40 (41%)
1 56 (58%)
2 1 (1%)
Serum LDH, IU/L
>ULN* 54 (56%)
Median (range) 756 (256-3021)
Abbreviations: IPI Z International Prognostic Index; LDH Z
lactate dehydrogenase; ULN Z upper limit of normal.
* Normal range is defined as 213-618 IU/L.
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response. In general, our institutional standard for con-
solidative RT was to administer 39.6 Gy. Patients with
known residual active disease after treatment with curative
intent received RT doses of 40 to 45 Gy.
Statistical analysis
The OS was calculated from the date of initial chemo-
therapy to the date of last follow-up visit or death of any
cause. The PFS was calculated from the start date of
immunochemotherapy to the date of documented progres-
sion, relapse, or death. Patients free of disease progression
and relapse were censored on the date of last follow-up visit
or contact. Survival analyses were done with the Kaplan-
Meier method, and statistical differences were evaluated
with the log-rank test (28). The maximum standardized
uptake value (SUVmax) based on body weight is routinely
recorded at our institution and was obtained from clinical
reports. The Mann-Whitney U (Wilcoxon rank sum) test
was used to evaluate differences in median SUVmax, with
P.05 considered significant. Because of the low number of
events in the group, univariate and multivariate analyses to
identify factors associated with disease progression or
recurrence were not done.
Results
Treatment
The characteristics of the 97 patients analyzed are listed in
Table 1. Their median age was 35 years, and a slight ma-
jority (nZ54, 56%) were women. All patients received 4 to
8 cycles of immunochemotherapy. Most patients (nZ50)
had received R-CHOP, with a median number of 6 cycles
(Table 2). R-HCVAD was given to 22 patients and R-
EPOCH to 25 patients. RT was given to 72 patients (74%).
Of patients treated with R-CHOP, most received RT
because this is standard practice at our institution when
R-CHOP is given; RT was omitted in 5 patients given
R-CHOP (10%) because of refusal (2 patients), prior sur-
gical resection at diagnosis (2 patients), and provider’s
preference (1 patient). Among the 22 patients treated with
R-HCVAD, 4 patients (18%) did not receive RT because of
either refusal (1 patient) or provider’s preference (3 pa-
tients). Hence, most patients treated with either R-CHOP or
R-HCVAD received radiation, in contrast to the R-EPOCH
group, for whom RT was not given to 16 patients (64%)
(Table 2). Our institutional policy is that RT can be omitted
for patients with PMBL treated with R-EPOCH. Of the 9
patients who did receive radiation after R-EPOCH, 4 were
treated for progressive disease and 5 received consolidative
RT because of physician’s preference. Eight patients
received an autologous stem cell transplant after immu-
nochemotherapy (7 for progressive disease and 1 for
consolidation), and 1 patient received an allogeneic stemcell transplant for disease relapse 1 year after an autologous
transplant; this patient was still alive at last follow-up.
Outcomes
At a median follow-up time of 57 months (range, 4-155
months), the 5-year PFS and OS rates for the entire group
were 91% and 99% (Fig. 1). Nine patients experienced
disease progression (nZ8) or disease relapse (nZ1) at a
median 4.6 months (range, 2.8-8.7 months) after treatment.
One patient died of disease, but no deaths related to treat-
ment or toxicity were reported. The median OS and PFS
times have not been reached. No statistically significant
differences were found in 5-year PFS among patients in the
3 immunochemotherapy-regimen groups (Fig. 2).
Toxicity
Treatment was well tolerated. Of the 72 patients who
received radiation, 40 (56%) experienced reversible grade 1
or 2 esophagitis or dermatitis related to the treatment. Five
patients experienced subacute pneumonitis requiring ste-
roids without significant chronic pulmonary deficits. One
patient experienced pericarditis after the third fraction of
RT, resulting in a treatment break; however, therapy was
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Fig. 2. Progression-free survival according to type of
immunochemotherapy for 97 patients with limited-stage
primary mediastinal B-cell lymphoma. R-CHOP Z ritux-
imab plus cyclophosphamide, doxorubicin, vincristine, and
prednisone; R-EPOCH Z rituximab plus dose-adjusted
etoposide, doxorubicin, cyclophosphamide, vincristine,
and prednisone; R-HCVAD Z rituximab plus hyper-
fractionated cyclophosphamide, vincristine, doxorubicin,
and dexamethasone.
Table 2 Treatment characteristics
Characteristic
R-CHOP
(nZ50)
R-HCVAD
(nZ22)
R-EPOCH
(nZ25)
No. of cycles
Median 6 6 6
Range 5-8 5-8 4-7
Radiation therapy
Consolidative
(presumed CR)
42 (84%) 17 (77.2%) 5 (20%)
Salvage 3 (6%) 1 (4.5%) 4 (16%)
No radiation 5 (10%) 4 (18.2%) 16 (64%)
Radiation dose
Median, Gy 39.6 39.6 39.6
Range, Gy 30-45 16.2-45 30.6-43.2
Radiation technique
3D 36 (80%) 16 (88.9%) 1 (11.1%)
IMRT 6 (13.3%) 1 (5.6%) 7 (77.8%)
Protons 3 (6.7%) 1 (5.6%) 1 (11.1%)
Abbreviations: 3D Z 3-dimensional; R-CHOP Z rituximab,
cyclophosphamide, doxorubicin, vincristine and prednisone; CR Z
complete response; IMRT Z intensity modulated radiation therapy;
R-EPOCH Z rituximab, vincristine, and prednisone with dose-
adjusted etoposide, doxorubicin and cyclophosphamide; R-HCVAD
Z rituximab, fractionated cyclophosphamide, vincristine, doxorubicin
and dexamethasone.
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tient had a normal ejection fraction and no chronic sequelae
from the pericarditis. Two secondary malignancies were
reported: a gallbladder spindle cell tumor in a patient who
received R-CHOP followed by consolidative RT to the
mediastinum, and therapy-related myelodysplastic syn-
drome in another patient after 6 cycles of R-HCVAD and
consolidative radiation to 30.6 Gy.
Long-term cardiac issues were observed in 5 patients.
Two patients had asymptomatic declines in ejection frac-
tion after R-CHOP that was detected by pre-RT cardiology
workup. Another patient treated with R-CHOP and RT hadOverall Survival
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Fig. 1. Overall survival (OS) (a) and progression-free survival
mediastinal B cell lymphoma.an asymptomatic drop in ejection fraction (from 65% to
54%) detected after the patient was referred to cardiology
for hypertension. A fourth patient had a nonfatal cardiac
arrest after R-CHOP without radiation. The fifth patient
experienced benign premature atrial contractions after 5
cycles of R-HCVAD and 45 Gy of RT.
PET-CT
At the time of diagnosis, 80 patients (82.5%) underwent
PET-CT imaging, 11 (11.3%) had a gallium scan, and 6
(6.1%) patients did not undergo functional imaging. Sixty-1.0
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Table 4a Progression/relapse events
5PS
Progression/
relapse
No progression/
relapse
Positive 5PS 3-5 7 35
Negative 5PS 1-2 0 26
Abbreviation: 5PS Z 5-point scale Deauville score.
Sensitivity Z 100%
Specificity Z 42.6%
PPV Z 16.7%
NPV Z 100%
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Table 4b Progression/relapse events
5PS
Progression/
relapse
No progression/
relapse
Positive 5PS 4-5 7 12
Negative 5PS 1-3 0 49
Abbreviation: 5PS Z 5-point scale Deauville score.
Sensitivity Z 100%
Specificity Z 80.3%
PPV Z 36.8%
NPV Z 100%
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after completion of all systemic therapy. The reasons for
not having a PET-CT scan at that time were having had a
gallium scan (nZ8), an interim PET-CT scan instead of an
end-of-immunochemotherapy scan (nZ9), and a scan not
done or unavailable (nZ12). Forty-two patients (62%) had
a 5PS of 3 and thus were considered by conventional
assessment criteria to have a positive scan. According to
this definition of positivity, the specificity and positive
predictive value (PPV) of the end-of-treatment PET-CT
scans were 42.6% and 16.7% (Tables 3, 4a and 4b).
Alternatively, if a 5PS of 4 or 5 were to be considered
positive, the specificity increased to 80.3% and the PPV
improved to 36.8%.
Of the 9 patients who had relapsed or progressive dis-
ease, 7 underwent PET-CT scans at the end of systemic
therapy, and 3 had biopsy to confirm the relapse or pro-
gression. Of the 4 patients who did not undergo biopsy, the
end-of-treatment PET-CT scan demonstrated a new avid
lesion, an increase in size of the initial mediastinal mass,
and increase in SUV avidity, or some combination of these
in comparison with the interim PET-CT scan. Of the 2
patients who experienced progressive disease but did not
have a postchemotherapy PET-CT scan, 1 patient had a
grossly positive gallium scan and died of disease after
salvage chemotherapy, an allogeneic stem cell transplant,
and palliative radiation to the mediastinum; the other had
interim PET-CT only and then experienced a biopsy-proven
relapse in the mediastinal radiation field 1 month after
consolidative RT. For the 7 patients with progressive dis-
ease and postimmunochemotherapy PET-CT scans, all had
a 5PS of 4 to 5, and the median SUVmax was 6.4 (Fig. 3).
When we compared the median SUVmax among patients
with an end-of-chemotherapy 5PS of 4 to 5 who did or did
not experience progressive disease or relapse, the difference
was statistically significant (median 6.4 vs 3.75, P<.0027).
All patients with a 5PS of 4 to 5 who did not have pro-
gressive disease had an SUVmax 5.4. The details of
treatment based on immunochemotherapy and end-of-
systemic treatment 5PS are depicted in Figure 4. When
we compared the PFS of patients with 5PS scores of 1 to 2
versus that in patients with scores of 3 to 5, the difference
was statistically significant (5-year PFS rates 100% vs 82%,
P<.031) (Fig. 5); however, the curves diverged further
when patients with a 5PS of 1 to 3 were compared with
those with a 5PS of 4 to 5 (5-year PFS, 100% vs 62%,
P<.000004).Table 3 End of immunochemotherapy PET-CT 5PS
5PS score 1 2 3 4 5
No. of patients 0 26 23 15 4
Progression/relapse 0 0 0 3 4
Abbreviations: 5PS Z 5-point scale Deauville score; CT Z
computed tomography; PET Z positron emission tomography.Discussion
In this retrospective analysis, we show that patients with
stage I/II PMBL who received RT after a complete response
to rituximab and doxorubicin-containing regimens had
excellent outcomes with limited acute toxicity. Roughly
three quarters of patients in our study had received RT.
Approximately 10% of patients experienced disease relapse
or progression after immunochemotherapy alone; however,
multimodality salvage therapy with RT, additional chemo-
therapy, and autologous stem cell transplantation was
effective, resulting in highly favorable 5-year OS rates for
this group of 99%.
Despite these excellent outcomes, the role of RT after
immunochemotherapy for PMBL remains unclear.      Pts without
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Fig. 3. Median standardized uptake values (SUVs) on
positron emission tomographyecomputed tomography
among patients with end-of-immunochemotherapy Deau-
ville 5-point scale of 4-5 with or without relapse.
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Fig. 4. Treatment and outcome based on type of chemoimmunotherapy and end-of-treatment PET-CT. (a) R-CHOP, rit-
uximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone; R-EPOCH, rituximab plus dose-adjusted etopo-
side, doxorubicin, cyclophosphamide, vincristine, and prednisone. (b) R-HCVAD, R-HCVAD, rituximab plus
hyperfractionated cyclophosphamide, vincristine, doxorubicin and dexamethasone. (c) R-EPOCH, rituximab plus dose-
adjusted etoposide, doxorubicin, cyclophosphamide, vincristine, and prednisone. ASCT Z allogeneic/autologous stem
cell transplantation; CCR Z continued complete response; chemo Z chemotherapy; CR Z complete response; PD Z
progressive disease; PET-CTZ positron emission tomographyecomputed tomography; RTZ radiation therapy; sChemoZ
salvage chemotherapy.
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other anthracycline-containing regimens such as R-
MACOP-B (rituximab, methotrexate, doxorubicin, cyclo-
phosphamide, vincristine, prednisone, and bleomycin)
suggest that consolidative RT improves outcomes after
complete response and after partial response to systemic
therapy (14, 29). This approach, however, was challenged
recently by a group from Memorial Sloan Kettering Cancer
Center, who published in abstract form the outcomes in
patients treated with R-CHOP-14 and 3 cycles of ifosfa-
mide, carboplatin, and etoposide (R-CHOP-ICE) without
RT. The 3-year PFS and OS rates were 78% and 88% (30).Perhaps of greater interest, though, are the outcomes in a
small series of patients treated with R-EPOCH without RT
in a phase II study at the NCI; the 5-year event-free survival
rate in that study was 93%, and the OS rate was 97%. Three
of 51 patients in the trial experienced persistent or pro-
gressive disease, which was salvaged by RT in 2 patients.
The 3-year PFS rate among 25 patients treated with R-
EPOCH in our series, 83%, was not as favorable as in the
NCI trial. Four patients in our study experienced disease
progression and received salvage therapy, which included
RT as a component of treatment in all 4 cases. Although a
prospective randomized trial addressing the question
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Fig. 5. Progression-free survival (PFS) according to Deauville 5-point scale (5Ps) at the end of initial chemotherapy. (a)
5PS 1-2 versus 5PS 3-5; (b) 5PS 1-3 versus 5PS 4-5. Cum Z cumulative.
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PMBL is ongoing (IELSG-37, NCT01599559), many cen-
ters including our own have adopted the strategy of treating
PMBL with R-EPOCH and assessing response with serial
PET scans without the routine use of RT.
Considerable interest has arisen in the potential utility of
functional imaging with PET-CT to guide decisions to be
made at the end of systemic therapy. In the phase II NCI
study, 36 patients had residual mediastinal masses and were
followed up with serial PET-CT scans; in 18 patients, up-
take of the masses was greater than that of the MBP after
chemotherapy, and residual lymphoma was found in 3 pa-
tients. In that study, PET-CT had a PPV of 17% and a
negative predictive value of 100%. The recent prospective
IELSG-26 study evaluated PET-CT after immunochemo-
therapy (R-CHOP, R-MACOP-B, or R-VACOP-B) in 115
patients treated for PMBL (22). Ninety-two percent of
patients in that study received RT. When the cutoff for
positivity was a 5PS 3, the PPV was similarly low at 18%.
However, changing the positive cutoff to a 5PS score of 4
improved the PPV of PET-CT after immunochemotherapy
to 32%. In a retrospective study from Italy, 37 patients
treated with immunochemotherapy and RT had PET eval-
uation after systemic treatment (18). Nine of 10 patients
with disease relapse or progression had a 5PS of 4 or 5. The
authors of that study concluded that a score of 4 or 5 should
be considered the positivity threshold for patients with
PMBL and that adopting this threshold would improve the
predictive power of PET-CT for this disease. In the current
study, for patients with localized disease, we found strik-
ingly similar sensitivities and specificities for PET-CT. Of
the 9 patients with relapse or progression, 7 had end-of-
systemic therapy PET-CT, and all had a 5PS of 4 to 5.
Raising the cutoff for positivity from 5PS of 3 to 4
improved the PPV of PET from 16.7% to 36.8%. This
change also improved specificity from 42.6% to 80.3%.
Further, among all patients with a 5PS of 4 to 5, those withdisease progression or persistent disease had higher SU
Vmax values (median 6.4 vs 3.75). All patients with an end-
of-immunochemotherapy PET-CT 5PS of 4 to 5 who did
not experience relapse or progression had an SUVmax of 5.4
or lower. PFS was significantly inferior for patients with
5PS of 4 to 5 in our series. When a 5PS of 3 was
considered positive, 62% of patients in our study had
positive end-of-chemotherapy PET-CT scans. In the NCI,
IELSG, and Italian studies, similar rates of FDG positivity
(defined as uptake greater than that of the MBP) were found
after immunochemotherapy (50%, 53%, and 68%, respec-
tively). Thus, by increasing the threshold for the definition
of positive PET scans in patients with PMBL, we may be
able to enhance the predictive accuracy of PET, which may
in turn help to guide decisions regarding RT, especially
when RT is not a routine part of therapy.
Despite blinded PET-CT evaluation by 2 expert radiol-
ogists, the current study is limited by its retrospective na-
ture. Furthermore, few biopsies were performed among our
patient cohort to exclude the possibility of a false positive
result (31, 32). Finally, there was heterogeneity regarding
the administration of consolidative RT, and it is therefore
challenging to assess the true sensitivity, specificity, and
predictive value of PET-CT imaging. Many of these limi-
tations may be overcome when the results from the IELSG-
37 randomized trial become available.
In this study, three quarters of patients were treated with
RT, and treatment was well tolerated. As expected, early
toxicity was grade 1 or 2 and reversible. When this report
was written, the follow-up time was too short to enable
assessment of the incidence of late cardiac morbidity and
second malignancies, which are of greatest concern in this
young patient population. Nevertheless, it is important to
recognize the ongoing evolution of RT techniques aimed at
reducing normal tissue exposure, and therefore we antici-
pate significant decreases in late toxicity as RT techniques
continue to improve. Through the use of involved site
Volume 92  Number 1  2015 Immunochemotherapy and Radiation for PMBL 121radiation, IMRT designed to avoid cardiac structures, and
customized incline boards to reduce breast exposure, the RT
approaches of today are undoubtedly far superior to tradi-
tional approaches (27). With a thoughtful and careful
approach, RT should be considered for patients at high risk
of progressive disease and relapse. Our findings indicate that
patients with a 5PS of 4 to 5 and an SUVmax greater than 5.4
after immunochemotherapydeven R-EPOCHdshould be
considered at high risk for relapse and thus are candidates
for therapy beyond serial imaging and observation.
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